Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet

Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that redu... Biopharmaceuticals, Cardiology, Regulatory Daiichi Sankyo, Esperion Therapeutics, bempedoic acid, ezetimibe
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news